http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7307071-B2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9b442f17c57e6903e584b8486085ac9
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
filingDate 2002-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2007-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26472776154a9b40d3594f31e86d589b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_644cddb43af475547fa4c2fc762031c7
publicationDate 2007-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-7307071-B2
titleOfInvention RAF-MEK-ERK pathway inhibitors to treat cancer
abstract Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009304694-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017183741-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011106298-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8618141-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11783366-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8242147-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7897623-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8637246-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8642759-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9279144-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013169858-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11087354-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017033113-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8124630-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8637553-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8076488-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7838541-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9233956-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3028699-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8796250-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8841330-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9084781-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010068738-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009298815-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8415345-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10428387-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11078540-B2
priorityDate 2001-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9736587-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03013540-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9426260-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400908
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395931
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID190551
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402946
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID453
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127700386
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393712
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399463
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393714
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123596
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1115
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534036
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5291
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45051774
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18594011
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394849
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID216239
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394850
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15324
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24441
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448897384
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393819
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87057646
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393829
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419552268
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107428
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128433595
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177

Total number of triples: 91.